Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Brachytherapy in Metastatic Esophageal Cancers
NCT02642809Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2016
- Primary completion
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in esophageal cancer, sponsored by Washington University School of Medicine. Primary endpoint: Number of Participants With Grade 3 or Higher Treatment Related Adverse Events. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02642809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02642809.